Aimmune Therapeutics, Inc. (AIMT) Lifted to “Buy” at Zacks Investment Research

Zacks Investment Research upgraded shares of Aimmune Therapeutics, Inc. (NASDAQ:AIMT) from a hold rating to a buy rating in a report released on Wednesday morning. Zacks Investment Research currently has $34.00 target price on the biotechnology company’s stock.

According to Zacks, “Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company’s characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California. “

Other equities research analysts have also issued research reports about the stock. Piper Jaffray Companies set a $38.00 price objective on shares of Aimmune Therapeutics and gave the company a buy rating in a research note on Thursday, July 27th. Wedbush reiterated an ourperform rating and issued a $42.00 price objective on shares of Aimmune Therapeutics in a research note on Monday, August 14th. Credit Suisse Group increased their price objective on shares of Aimmune Therapeutics from $36.00 to $45.00 and gave the company an outperform rating in a research note on Monday, October 23rd. Finally, BidaskClub lowered shares of Aimmune Therapeutics from a hold rating to a sell rating in a research note on Friday, August 11th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the stock. The company presently has an average rating of Buy and an average target price of $46.75.

Shares of Aimmune Therapeutics (NASDAQ:AIMT) opened at $33.77 on Wednesday. Aimmune Therapeutics has a one year low of $15.97 and a one year high of $37.50.

Aimmune Therapeutics (NASDAQ:AIMT) last posted its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($0.63) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.72) by $0.09. equities research analysts expect that Aimmune Therapeutics will post -2.48 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This article was originally published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this article on another domain, it was stolen and reposted in violation of international copyright and trademark laws. The original version of this article can be accessed at https://sportsperspectives.com/2017/11/11/aimmune-therapeutics-inc-aimt-lifted-to-buy-at-zacks-investment-research.html.

In other news, insider Douglas T. Sheehy sold 47,425 shares of the firm’s stock in a transaction that occurred on Monday, October 23rd. The shares were sold at an average price of $34.44, for a total transaction of $1,633,317.00. Following the completion of the sale, the insider now owns 34,300 shares in the company, valued at approximately $1,181,292. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Mary M. Rozenman sold 30,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 7th. The stock was sold at an average price of $22.50, for a total transaction of $675,000.00. Following the sale, the insider now owns 30,129 shares of the company’s stock, valued at approximately $677,902.50. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 315,815 shares of company stock valued at $8,337,379. 24.56% of the stock is currently owned by company insiders.

Several hedge funds have recently modified their holdings of the company. SG Americas Securities LLC increased its stake in shares of Aimmune Therapeutics by 10.1% during the 2nd quarter. SG Americas Securities LLC now owns 5,451 shares of the biotechnology company’s stock worth $112,000 after purchasing an additional 499 shares during the last quarter. American International Group Inc. increased its stake in shares of Aimmune Therapeutics by 7.1% during the 1st quarter. American International Group Inc. now owns 16,184 shares of the biotechnology company’s stock worth $352,000 after purchasing an additional 1,070 shares during the last quarter. Teachers Advisors LLC increased its stake in shares of Aimmune Therapeutics by 2.6% during the 1st quarter. Teachers Advisors LLC now owns 44,349 shares of the biotechnology company’s stock worth $964,000 after purchasing an additional 1,120 shares during the last quarter. Legal & General Group Plc increased its stake in shares of Aimmune Therapeutics by 26.6% during the 2nd quarter. Legal & General Group Plc now owns 7,776 shares of the biotechnology company’s stock worth $160,000 after purchasing an additional 1,634 shares during the last quarter. Finally, Strs Ohio increased its stake in shares of Aimmune Therapeutics by 6.1% during the 2nd quarter. Strs Ohio now owns 34,600 shares of the biotechnology company’s stock worth $711,000 after purchasing an additional 2,000 shares during the last quarter. Institutional investors own 72.84% of the company’s stock.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Get a free copy of the Zacks research report on Aimmune Therapeutics (AIMT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply